Skip to main content
Walvax Biotechnology Co.,Ltd. logo

Walvax Biotechnology Co.,Ltd. — Investor Relations & Filings

Ticker · 300142 ISIN · CNE100000WN2 LEI · 300300H82R2DIQXA8N24 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,790 across all filing types
Latest filing 2022-04-28 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 300142

About Walvax Biotechnology Co.,Ltd.

https://www.walvax.com

Walvax Biotechnology Co.,Ltd. is a biopharmaceutical enterprise specializing in the research, development, production, and distribution of vaccines and other biological products. The company focuses on modern biotechnology to address public health challenges through a diverse portfolio of preventive vaccines. Key products include the 13-valent pneumococcal polysaccharide conjugate vaccine (PCV13), the bivalent human papillomavirus (HPV) vaccine, and various combination vaccines for meningitis and Haemophilus influenzae type b (Hib). Walvax operates advanced R&D platforms and manufacturing facilities that comply with international quality standards. The company is actively involved in the development of next-generation vaccine technologies, including mRNA and recombinant protein platforms, aiming to provide affordable and high-quality immunization solutions for global markets.

Recent filings

Filing Released Lang Actions
关于子公司对外捐赠的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement from a company regarding a decision made by its board of directors about a donation by a subsidiary. It details the board meeting resolutions, the purpose and impact of the donation, and includes opinions from independent directors and the supervisory board. There is no financial data, no mention of financial results, no regulatory certifications, or report attachments. The document is an announcement of a corporate action related to social responsibility and board decisions, not a financial report or regulatory filing. It fits best under Regulatory Filings (RNS) as a general corporate announcement that does not fit other specific categories.
2022-04-28 Chinese
第四届监事会第二十六次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a resolution announcement from the Supervisory Board of Yunnan Watson Biotechnology Co., Ltd. It details the approval of the company's 2022 first quarter report, adjustments to stock option exercise prices, share repurchase price limits, and a donation proposal. The document includes voting results and confirms compliance with relevant laws and regulations. It references the 2022 first quarter report but does not contain the report itself or detailed financial statements. The document is relatively short (2452 characters) and serves as an official announcement of supervisory board decisions rather than a full financial report. Therefore, it fits best under Regulatory Filings (RNS) as it is a formal regulatory announcement of supervisory board resolutions and approvals, not the actual quarterly report or other specific report types.
2022-04-28 Chinese
关于调整2020年股票期权激励计划股票期权行权价格的公告
Capital/Financing Update Classification · 95% confidence The document is an official announcement from a company regarding the adjustment of the stock option exercise price under its 2020 stock option incentive plan. It details board and supervisory meetings, approvals, legal opinions, and the rationale for the price adjustment. The document does not contain financial statements or comprehensive financial data but rather focuses on corporate governance actions related to stock options. It is not a full annual or interim report, nor an earnings release or audit report. It is a regulatory announcement about a capital-related change (adjustment of stock option exercise price) but does not announce new share issuance or capital increase per se. The closest fitting category is 'Capital/Financing Update (CAP)' as it relates to changes in the company's capital structure through stock option plan adjustments. The document length is under 5,000 characters, but it is a detailed announcement, not merely a report publication notice or certification. Therefore, the classification is CAP with high confidence.
2022-04-28 Chinese
第四届董事会第三十四次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of resolutions passed at a board meeting of Yunnan Watson Biotechnology Co., Ltd. It includes details about the meeting date, attendance, and voting results on various agenda items such as approval of the 2022 first quarter report, adjustments to stock option exercise prices, share repurchase price limits, and donations by a subsidiary. The document does not contain the full financial report itself but references the 2022 first quarter report as available on an external disclosure website. The content focuses on board decisions and approvals rather than presenting comprehensive financial data or management discussion. Therefore, this document fits best under the category of Board/Management Information (MANG), as it announces board meeting resolutions and management decisions.
2022-04-28 Chinese
北京国枫律师事务所关于公司2020年股票期权激励计划之调整行权价格事项的法律意见书
Regulatory Filings Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding the adjustment of the exercise price of a 2020 stock option incentive plan for a company. It references specific legal regulations, company board and shareholder approvals, and details the adjustment calculation. The document is a standalone legal opinion related to a stock option plan adjustment, not a financial report, earnings release, or general announcement. It does not contain financial statements or quarterly/yearly financial data. It is a specialized legal report on a corporate governance and compensation matter. Therefore, it fits best under the category of Regulatory Filings (RNS) as it is a legal compliance document that does not fit other specific categories like Remuneration Information or Board/Management Information, since it is a legal opinion rather than a direct announcement of management changes or compensation details.
2022-04-28 Chinese
2022年第一季度报告披露提示性公告
Report Publication Announcement Classification · 95% confidence The document is a short announcement (395 characters) indicating that the company has disclosed its 2022 first quarter report on a regulatory website. It states the report was approved by the board and is available for investors to review. The text does not contain the actual financial data or detailed report content, but rather serves as a notification of the report's publication. According to the MENU VS MEAL RULE, such a brief notice announcing the availability of a report is classified as a Report Publication Announcement (RPA), not the report itself (IR).
2022-04-28 Chinese

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.